Hanna Hend, Bahna Paul, Reitzel Ruth, Dvorak Tanya, Chaiban Gassan, Hachem Ray, Raad Issam
University of Texas MD Anderson Cancer Center, Department of Infectious Diseases, Infection Control and Employee Health, Houston, TX 77030, USA.
Antimicrob Agents Chemother. 2006 Oct;50(10):3283-8. doi: 10.1128/AAC.01622-05.
We investigated the efficacies and durability of novel antimicrobial central venous catheters (CVCs) in preventing the adherence of microbial organisms to the surfaces of the CVCs. Novel antimicrobial CVCs investigated in this in vitro study were impregnated with antibiotics (minocycline and rifampin), with Oligon agent (silver, platinum, and carbon black), with approved antiseptics (chlorhexidine and silver sulfadiazine), or with a novel antiseptic agent, gendine, which contains gentian violet and chlorhexidine. When tested against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa, gendine-coated CVC segments provided protection against bacterial adherence significantly more than all other types of tested CVCs (P < 0.05). Gendine-coated CVCs also provided better protection against Candida albicans and Candida parapsilosis than CVCs impregnated with antibiotics or with silver, platinum, and carbon (P < 0.02). After 28 days of being soaked in serum, the CVCs impregnated with chlorhexidine and silver sulfadiazine and the CVCs impregnated with silver, platinum, and carbon had lost antimicrobial activity against MRSA, P. aeruginosa, and C. parapsilosis, and the CVCs impregnated with minocycline and rifampin had lost activity against P. aeruginosa and C. parapsilosis. The CVCs impregnated with gendine maintained antimicrobial activities against MRSA, P. aeruginosa, and C. parapsilosis after 28 days of being soaked in serum. Central venous catheters impregnated with the novel investigational antiseptic gendine showed in vitro efficacy and provided protection against bacterial adherence more than other approved novel antimicrobial-coated CVCs.
我们研究了新型抗菌中心静脉导管(CVC)在防止微生物附着于CVC表面方面的有效性和耐久性。本体外研究中所研究的新型抗菌CVC分别浸渍了抗生素(米诺环素和利福平)、含Oligon制剂(银、铂和炭黑)、已获批准的防腐剂(氯己定和磺胺嘧啶银)或一种新型防腐剂gendine(其含有龙胆紫和氯己定)。在针对耐甲氧西林金黄色葡萄球菌(MRSA)和铜绿假单胞菌进行测试时,涂有gendine的CVC段对细菌附着的防护作用明显优于所有其他类型的受试CVC(P<0.05)。与浸渍了抗生素或银、铂和炭的CVC相比,涂有gendine的CVC对白色念珠菌和近平滑念珠菌也提供了更好的防护(P<0.02)。在血清中浸泡28天后,浸渍了氯己定和磺胺嘧啶银的CVC以及浸渍了银、铂和炭的CVC对MRSA、铜绿假单胞菌和近平滑念珠菌失去了抗菌活性,而浸渍了米诺环素和利福平的CVC对铜绿假单胞菌和近平滑念珠菌失去了活性。浸渍了gendine的CVC在血清中浸泡28天后仍保持对MRSA、铜绿假单胞菌和近平滑念珠菌的抗菌活性。浸渍了新型研究用防腐剂gendine的中心静脉导管在体外显示出有效性,并且比其他已获批准的新型抗菌涂层CVC提供了更好的抗细菌附着保护作用。